Canadian Corporate News - Medicure Meets Primary Endpoints in Phase II Diabetic Hypertension Study.
WINNIPEG, MANITOBA, Sep 14, 2005 (CCNMatthews via COMTEX) — Conference Call Today at 10:30 AM Eastern to Discuss Positive MATCHED Results
Related Results
Mylan Receives Approval for Lisinopril and Lisinopril/HCTZIvax’s lisinopril gets tentative OKTeva Announces Approval Of Lisinopril Tablets And Lisinopril HCTZ TabletsGenerics firms win approval for lisinoprilEon Labs Receives Approval for Lisinopril/HCTZ Tablets
Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development company, is pleased to announce that MC-4232 met primary blood pressure and metabolic endpoints in the Phase II MATCHED study. The study evaluated MC-4232, a combination of MC-1 and the ACE inhibitor, lisinopril, in the treatment of coexisting diabetes and hypertension. Based on these positive results, the Company plans to move forward with a pivotal Phase III …
Read the rest of this article with a Free Trial at HighBeam Research.
